Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 2:40 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 205 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: levonorgestrel Clear all

Conditions: Menorrhagia
Interventions: Levonorgestrel IUS (Mirena, BAY86-5028), Medroxyprogesterone acetate; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 37
States / cities: Tucson, Arizona • Beverly Hills, California • Carmichael, California + 32 more

Conditions: Pregnancy
Interventions: levonorgestrel 0.75mg taken twice 12 hours apart (Plan B) and condoms; Drug
Lead sponsor: University of Washington; Other
Eligibility: 16 Years to 60 Years · Female only
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Contraception
Interventions: Mirena (levonorgestrel-releasing intrauterine system); Device
Lead sponsor: University of Louisville; Other
Eligibility: 15 Years to 45 Years · Female only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Contraception
Interventions: Kyleena Intrauterine System, Mirena Intrauterine System; Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Tulsa, Oklahoma

Conditions: Mucosal Inflammation, Contraceptive; Complications, Intrauterine
Interventions: Copper IUD, Etonogestrel implant, Levonorgestrel IUS, DMPA Sub-cutaneous; Drug
Lead sponsor: Eastern Virginia Medical School; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 112 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Premenstrual Syndrome
Interventions: Levonorgestrel/Ethinyl Estradiol; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 48
States / cities: Huntsville, Alabama • Peoria, Arizona • Phoenix, Arizona + 40 more

Conditions: Healthy Participants
Interventions: EE/LNG, Baxdrostat; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 35 Years to 75 Years · Female only
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Contraception
Interventions: Mirena, Paragard; Device
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Pain Control With IUD Insertion
Interventions: Ketorolac, Normal Saline; Drug
Lead sponsor: Lynn Ngo; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: San Diego, California

Conditions: Endometriosis
Interventions: norethindrone acetate (NETA), Placebo; Drug
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 13 Years to 24 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy
Interventions: Ortho-Cyclen, AG200-15; Drug
Lead sponsor: Agile Therapeutics; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Intrauterine Devices
Interventions: Intrauterine device; Device
Lead sponsor: Bayer; Industry
Eligibility: Up to 50 Years · Female only
Enrollment: 326,658 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 4
States / cities: Oakland, California • Pasadena, California • Indianapolis, Indiana + 1 more

Conditions: Healthy Volunteer
Interventions: PTI-428, Placebo, ethinyl estradiol and levonorgestrel; Drug · Other
Lead sponsor: Proteostasis Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 94 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Bone Mineral Density
Interventions: 91-day Levonorgestrel Oral Contraceptive, 28-day Levonorgestrel Oral Contraceptive; Drug
Lead sponsor: Duramed Research; Industry
Eligibility: 12 Years to 18 Years · Female only
Enrollment: 1,361 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 46
States / cities: Phoenix, Arizona • Tucson, Arizona • North Little Rock, Arkansas + 39 more

Conditions: HIV Infections
Interventions: Ethinyl estradiol/levonorgestrel, Medroxyprogesterone acetate; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 16 Years to 35 Years · Female only
Enrollment: 6,360 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999 – 2002
U.S. locations: 1
States / cities: Research Triangle Park, North Carolina

Conditions: Postpartum Period
Interventions: Post-Placenta Mirena Insertion, Interval Insertion; Device
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 14 Years to 45 Years · Female only
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: HIV Infections
Interventions: GSK3640254, Portia; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Anorexia Nervosa
Interventions: Transdermal estrogen, Placebos; Drug
Lead sponsor: Pouneh K. Fazeli, MD; Other
Eligibility: 19 Years to 45 Years · Female only
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Opiate Addiction, Pregnancy, Contraceptive Behavior, Sexual Behavior
Interventions: Nexplanon (etonogestrel contraceptive implant), Standard postpartum contraceptive care; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Obesity, Overweight
Interventions: Eloralintide, Combined oral contraceptive; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Daytona Beach, Florida • Dallas, Texas

Conditions: Contraception
Interventions: LNG-EC, UPA-EC; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Contraception
Interventions: Levonorgestrel-releasing IUD (Mirena); Device
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older · Female only
Enrollment: 168 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Contraception
Interventions: DMPA 150, DMPA 300, DMPA 104; Drug
Lead sponsor: FHI 360; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: HIV, Contraception
Interventions: TFV IVR, TFV/LNG IVR, Placebo IVR; Drug · Other
Lead sponsor: CONRAD; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Norfolk, Virginia

Search by objective public record fields.

Study in Women With Idiopathic Menorrhagia to Determine the Reduction in Menstrual Blood Loss (MBL) After Treatment With the Levonorgestrel-releasing Intrauterine System (IUS)

Randomized Trial of Advanced Provision Emergency Contraception Among Women With Gonorrhea or Chlamydia

Safety and Expulsion of Delayed Versus Immediate Postpartum Intrauterine Device Placement

Immediate Postpartum Insertion of Contraceptive Intrauterine Devices

Impact of Contraceptives on Cervico-Vaginal Mucosa

Study Evaluating Levonorgestrel/Ethinyl Estradiol (LNG/EE) in PMS

A Study to Investigate the Pharmacokinetics of Ethinyl Estradiol and Levonorgestrel When Given Alone and in Combination With Baxdrostat in Healthy Females of Non-childbearing Potential

Immediate Postplacental IUD Insertion

Pain Control for Intrauterine Device Placement: A Trial of Ketorolac Prior to Intrauterine Device Placement

IUD and Norethindrone Acetate for Treatment of Endometriosis

AG200-15 Transdermal Contraceptive Delivery System (TCDS) of Levonorgestrel and Ethinyl Estradiol

Study on Medical Records of Women Using an Intrauterine Device (IUD) to Analyze the Risks That the IUD Will be Expelled or Perforates the Womb in Relation to Breastfeeding, the Point in Time When the IUD Was Inserted After Childbirth and in Relation to Different Types of IUDs

Study to Assess the Safety, Tolerability, PK, ECG Effects, Food Effect, and Drug-drug Interaction (DDI) of Hormonal Contraceptives of PTI-428 in Healthy Female Volunteers

A Multicenter Study to Evaluate the Effects of a 91-day Oral Contraceptive on Bone Mineral Density in Adolescent Females

Hormonal Birth Control and the Risk of Acquiring HIV

Mirena Intrauterine System Timing of Insertion: A Randomized Controlled Trial

Effect of GSK3640254 on the Pharmacokinetics of a Combination Oral Contraceptive

Transdermal Estrogen in Women With Anorexia Nervosa

Immediate Postpartum Nexplanon Placement in Opioid Dependent Women

A Study of Eloralintide (LY3841136) in Female Participants With Obesity or Overweight

EC PK in Women With Normal and Obese BMI

Postplacental or Delayed Insertion of the Levonorgestrel-releasing Intrauterine Device (IUD) After Vaginal Delivery

Pharmacodynamics and Pharmacokinetics Study of Existing DMPA Contraceptive Methods

Phase I One-month Safety, PK, PD, and Acceptability Study of IVR Releasing TFV and LNG or TFV Alone